Comprehensive Management of Congestive Heart Failure

Staging and Risk Stratification

The American College of Cardiology and American Heart Association recommend classifying patients with heart failure using the ACC/AHA staging system (A through D) to guide treatment intensity and prognosis 1, 2
For Stage A (at risk, no structural disease), focus on aggressive control of hypertension with target BP <130/80 mmHg if cardiovascular risk >10%, treat hyperlipidemia, and consider ACE inhibitors or ARBs in appropriate patients 3
For Stage B (structural disease, no symptoms), initiate ACE inhibitors or ARBs and beta-blockers in all patients with reduced ejection fraction, particularly post-myocardial infarction 4

The American College of Cardiology recommends starting enalapril 2.5-5 mg twice daily and uptitrating to target dose of 10-20 mg twice daily over 2-4 weeks for ACE inhibitor therapy 7, 8
ACE inhibitors reduce mortality and hospitalization in all symptomatic patients with LVEF ≤40% 4
Beta-blockers reduce mortality and hospitalization when added to ACE inhibitors 4
Mineralocorticoid receptor antagonists reduce mortality in patients with recent or current Class IV symptoms 7, 9
SGLT2 inhibitors provide mortality benefit in both HFrEF and HFpEF 4, 3

The European Heart Journal recommends implantable cardioverter-defibrillator (ICD) for primary prevention in patients with LVEF ≤30-35%, NYHA Class II-III symptoms on optimal medical therapy for ≥3 months, and life expectancy >1 year 4, 9
Cardiac resynchronization therapy (CRT) is indicated in patients with LVEF ≤35%, sinus rhythm, NYHA Class II-IV symptoms on optimal medical therapy, and QRS ≥150 ms with left bundle branch block morphology 4, 9

Administer IV loop diuretics at doses equal to or exceeding chronic oral daily dose within 1 hour of presentation for hospitalized patients with acute heart failure 6, 10
Continue ACE inhibitors and beta-blockers during hospitalization unless hemodynamically unstable 6

Restrict sodium intake to <2-3 g/day and measure weight daily at the same time 7, 2
Encourage regular physical activity and exercise training in stable ambulatory patients (NYHA Class I-III) to improve functional capacity and quality of life 7, 8, 9

Monitor symptoms, weight, blood pressure, heart rate, volume status, renal function, and electrolytes at each visit 2, 6, 9
Measure natriuretic peptides (BNP or NT-proBNP) at baseline and consider serial measurements to guide therapy and assess prognosis 3, 10